+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Somatostatin Analogs Market Size, Share & Trends Analysis Report by Type (Octreotide, Lanreotide, Pasireotide), Application (Acromegaly, NET), End-use (Hospitals, Clinics), and Region with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 90 Pages
  • May 2025
  • Region: Global
  • Grand View Research
  • ID: 6098133
Description Jump to:
The Somatostatin Analogs Market was valued at USD 5.22 billion in 2024, and is projected to reach USD 11.1 billion by 2030, rising at a CAGR of 13.30%. Increasing awareness of diseases such as acromegaly and neuroendocrine tumors is expected to be the vital impact rendering driver.

Acromegaly is a chronic endocrine condition caused by excessive growth hormone production, often due to a pituitary adenoma. In 2023, approximately 4,600 people per million globally were affected by acromegaly, with an estimated 116.9 new cases diagnosed annually per million, a number that continues to rise. The disorder is usually diagnosed around age 40 in men and 45 in women, though it often begins in the third decade of life. Hence, the increasing prevalence of acromegaly drives the somatostatin analogs market.

The growing rate of NET diagnoses in countries such as South Korea, Japan, and India and increasing per capita income are significant market drivers. In addition, rising investments from pharmaceutical companies are expected to create lucrative growth opportunities. Existence of different online portals providing related information on various diseases is anticipated to create awareness among the population. For instance, Neuroendocrine Cancer Awareness Network provides all the information related to their symptoms, available treatment options and disease management.

Somatostatin Analogs Market Highlights

  • By type, octreotide dominated the somatostatin analogs market, with a revenue share of 36.3% in 2024.
  • The pasireotide segment is expected to grow at the fastest CAGR over the forecast period.
  • By application, the NET segment dominated the somatostatin analogs market with the largest revenue share in 2024 and is expected to grow at the fastest CAGR over the forecast period.
  • Hospitals led the somatostatin analogs market, accounting for the largest revenue share in 2024.
  • Hospitals dominated the market in 2024, and the clinics segment is expected to grow at the fastest CAGR of 14.4% over the forecast period.
  • North America dominated the global market owing to the presence of key players in the region.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Application
1.2.3. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Somatostatin Analogs Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
Chapter 4. Somatostatin Analogs Market: Type Business Analysis
4.1. Type Market Share, 2024 & 2030
4.2. Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
4.4. Octreotide
4.4.1. Octreotide Market, 2018-2030 (USD Million)
4.5. Lanreotide
4.5.1. Lanreotide Market, 2018-2030 (USD Million)
4.6. Pasireotide
4.6.1. Pasireotide Market, 2018-2030 (USD Million)
4.7. Others
4.7.1. Others Segment Market, 2018-2030 (USD Million)
Chapter 5. Somatostatin Analogs Market: Application Business Analysis
5.1. Application Market Share, 2024 & 2030
5.2. Application Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
5.4. Acromegaly
5.4.1. Somatostatin Analogs Market, in Acromegaly, 2018-2030 (USD Million)
5.5. NET
5.5.1. Somatostatin Analogs Market, in NET, 2018-2030 (USD Million)
5.6. Others
5.6.1. Somatostatin Analogs Market, in Others, 2018-2030 (USD Million)
Chapter 6. Somatostatin Analogs Market: End Use Business Analysis
6.1. End Use Market Share, 2024 & 2030
6.2. End Use Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
6.4. Hospitals
6.4.1. Hospitals Segment Market, 2018-2030 (USD Million)
6.5. Clinics
6.5.1. Clinics Segment Market, 2018-2030 (USD Million)
6.6. Others
6.6.1. Others Segment Market, 2018-2030 (USD Million)
Chapter 7. Somatostatin Analogs Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030
7.4. North America
7.4.1. North America Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018-2030 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Regulatory Framework
7.4.2.3. Competitive Insights
7.4.2.4. U.S. Somatostatin Analogs Market Estimates And Forecasts, 2018-2030 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Regulatory Framework
7.4.3.3. Competitive Insights
7.4.3.4. Canada Somatostatin Analogs Market Estimates And Forecasts, 2018-2030 (USD Million)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Regulatory Framework
7.4.4.3. Competitive Insights
7.4.4.4. Mexico Somatostatin Analogs Market Estimates And Forecasts, 2018-2030 (USD Million)
7.5. Europe
7.5.1. Europe Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018-2030 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Regulatory Framework
7.5.2.3. Competitive Insights
7.5.2.4. UK Somatostatin Analogs Market Estimates And Forecasts, 2018-2030 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Regulatory Framework
7.5.3.3. Competitive Insights
7.5.3.4. Germany Somatostatin Analogs Market Estimates And Forecasts, 2018-2030 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Regulatory Framework
7.5.4.3. Competitive Insights
7.5.4.4. France Somatostatin Analogs Market Estimates And Forecasts, 2018-2030 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Regulatory Framework
7.5.5.3. Competitive Insights
7.5.5.4. Italy Somatostatin Analogs Market Estimates And Forecasts, 2018-2030 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Regulatory Framework
7.5.6.3. Competitive Insights
7.5.6.4. Spain Somatostatin Analogs Market Estimates And Forecasts, 2018-2030 (USD Million)
7.5.7. Denmark
7.5.7.1. Key Country Dynamics
7.5.7.2. Regulatory Framework
7.5.7.3. Competitive Insights
7.5.7.4. Denmark Somatostatin Analogs Market Estimates And Forecasts, 2018-2030 (USD Million)
7.5.8. Sweden
7.5.8.1. Key Country Dynamics
7.5.8.2. Regulatory Framework
7.5.8.3. Competitive Insights
7.5.8.4. Sweden Somatostatin Analogs Market Estimates And Forecasts, 2018-2030 (USD Million)
7.5.9. Norway
7.5.9.1. Key Country Dynamics
7.5.9.2. Regulatory Framework
7.5.9.3. Competitive Insights
7.5.9.4. Norway Somatostatin Analogs Market Estimates And Forecasts, 2018-2030 (USD Million)
7.5.10. Russia
7.5.10.1. Key Country Dynamics
7.5.10.2. Regulatory Framework
7.5.10.3. Competitive Insights
7.5.10.4. Russia Somatostatin Analogs Market Estimates And Forecasts, 2018-2030 (USD Million)
7.6. Asia Pacific
7.6.1. Asia Pacific Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018-2030 (USD Million)
7.6.2. India
7.6.2.1. Key Country Dynamics
7.6.2.2. Regulatory Framework
7.6.2.3. Competitive Insights
7.6.2.4. India Somatostatin Analogs Market Estimates And Forecasts, 2018-2030 (USD Million)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Regulatory Framework
7.6.3.3. Competitive Insights
7.6.3.4. China Somatostatin Analogs Market Estimates And Forecasts, 2018-2030 (USD Million)
7.6.4. South Korea
7.6.4.1. Key Country Dynamics
7.6.4.2. Regulatory Framework
7.6.4.3. Competitive Insights
7.6.4.4. South Korea Somatostatin Analogs Market Estimates And Forecasts, 2018-2030 (USD Million)
7.6.5. Hong Kong
7.6.5.1. Key Country Dynamics
7.6.5.2. Regulatory Framework
7.6.5.3. Competitive Insights
7.6.5.4. Hong Kong Somatostatin Analogs Market Estimates And Forecasts, 2018-2030 (USD Million)
7.6.6. Australia
7.6.6.1. Key Country Dynamics
7.6.6.2. Regulatory Framework
7.6.6.3. Competitive Insights
7.6.6.4. Australia Somatostatin Analogs Market Estimates And Forecasts, 2018-2030 (USD Million)
7.6.7. Singapore
7.6.7.1. Key Country Dynamics
7.6.7.2. Regulatory Framework
7.6.7.3. Competitive Insights
7.6.7.4. Singapore Somatostatin Analogs Market Estimates And Forecasts, 2018-2030 (USD Million)
7.6.8. Japan
7.6.8.1. Key Country Dynamics
7.6.8.2. Regulatory Framework
7.6.8.3. Competitive Insights
7.6.8.4. Japan Somatostatin Analogs Market Estimates And Forecasts, 2018-2030 (USD Million)
7.6.9. Thailand
7.6.9.1. Key Country Dynamics
7.6.9.2. Regulatory Framework
7.6.9.3. Competitive Insights
7.6.9.4. Thailand Somatostatin Analogs Market Estimates And Forecasts, 2018-2030 (USD Million)
7.7. Latin America
7.7.1. Latin America Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018-2030 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Regulatory Framework
7.7.2.3. Competitive Insights
7.7.2.4. Brazil Somatostatin Analogs Market Estimates And Forecasts, 2018-2030 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Regulatory Framework
7.7.3.3. Competitive Insights
7.7.3.4. Argentina Somatostatin Analogs Market Estimates And Forecasts, 2018-2030 (USD Million)
7.8. Middle East & Africa
7.8.1. Middle East & Africa Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018-2030 (USD Million)
7.8.2. Kuwait
7.8.2.1. Key Country Dynamics
7.8.2.2. Regulatory Framework
7.8.2.3. Competitive Insights
7.8.2.4. Kuwait Somatostatin Analogs Market Estimates And Forecasts, 2018-2030 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Regulatory Framework
7.8.3.3. Competitive Insights
7.8.3.4. Saudi Arabia Somatostatin Analogs Market Estimates And Forecasts, 2018-2030 (USD Million)
7.8.4. South Africa
7.8.4.1. Key Country Dynamics
7.8.4.2. Regulatory Framework
7.8.4.3. Competitive Insights
7.8.4.4. South Africa Somatostatin Analogs Market Estimates And Forecasts, 2018-2030 (USD Million)
7.8.5. UAE
7.8.5.1. Key Country Dynamics
7.8.5.2. Regulatory Framework
7.8.5.3. Competitive Insights
7.8.5.4. UAE Somatostatin Analogs Market Estimates And Forecasts, 2018-2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. Novo Nordisk A/S
8.5.1.1. Overview
8.5.1.2. Financial Performance
8.5.1.3. Type Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Pfizer Inc.
8.5.2.1. Overview
8.5.2.2. Financial Performance
8.5.2.3. Type Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Eli Lilly and Company
8.5.3.1. Overview
8.5.3.2. Financial Performance
8.5.3.3. Type Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Medical Device Business Services, Inc.
8.5.4.1. Overview
8.5.4.2. Financial Performance
8.5.4.3. Type Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Johnson & Johnson Services, Inc.
8.5.5.1. Overview
8.5.5.2. Financial Performance
8.5.5.3. Type Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Stryker
8.5.6.1. Overview
8.5.6.2. Financial Performance
8.5.6.3. Type Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Ultragenyx Pharmaceutical Inc.
8.5.7.1. Overview
8.5.7.2. Financial Performance
8.5.7.3. Type Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Alexion Pharmaceuticals, Inc.
8.5.8.1. Overview
8.5.8.2. Financial Performance
8.5.8.3. Type Benchmarking
8.5.8.4. Strategic Initiatives
List of Tables
Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. Global somatostatin analogs market, by region, 2018-2030 (USD Million)
Table 4. Global somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 5. Global somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 6. Global somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 7. North America somatostatin analogs market, by country, 2018-2030 (USD Million)
Table 8. North America somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 9. North America somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 10. North America somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 11. U.S. somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 12. U.S. somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 13. U.S. somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 14. Canada somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 15. Canada somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 16. Canada somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 17. Mexico somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 18. Mexico somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 19. Mexico somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 20. Europe somatostatin analogs market, by country, 2018-2030 (USD Million)
Table 21. Europe somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 22. Europe somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 23. Europe somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 24. UK somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 25. UK somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 26. UK somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 27. Germany somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 28. Germany somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 29. Germany somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 30. France somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 31. France somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 32. France somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 33. Italy somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 34. Italy somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 35. Italy somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 36. Spain somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 37. Spain somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 38. Spain somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 39. Denmark somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 40. Denmark somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 41. Denmark somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 42. Sweden somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 43. Sweden somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 44. Sweden somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 45. Norway somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 46. Norway somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 47. Norway somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 48. Russia somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 49. Russia somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 50. Russia somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 51. Asia Pacific somatostatin analogs market, by country, 2018-2030 (USD Million)
Table 52. Asia Pacific somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 53. Asia Pacific somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 54. Asia Pacific somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 55. India somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 56. India somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 57. India somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 58. China somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 59. China somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 60. China somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 61. South Korea somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 62. South Korea somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 63. South Korea somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 64. Hong Kong somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 65. Hong Kong somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 66. Hong Kong somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 67. Australia somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 68. Australia somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 69. Australia somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 70. Singapore somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 71. Singapore somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 72. Singapore somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 73. Japan somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 74. Japan somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 75. Japan somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 76. Thailand somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 77. Thailand somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 78. Thailand somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 79. Latin America somatostatin analogs market, by country, 2018-2030 (USD Million)
Table 80. Latin America somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 81. Latin America somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 82. Latin America somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 83. Brazil somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 84. Brazil somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 85. Brazil somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 86. Argentina somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 87. Argentina somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 88. Argentina somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 89. Middle East & Africa somatostatin analogs market, by country, 2018-2030 (USD Million)
Table 90. Middle East & Africa somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 91. Middle East & Africa somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 92. Middle East & Africa somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 93. Kuwait somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 94. Kuwait somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 95. Kuwait somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 96. Saudi Arabia somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 97. Saudi Arabia somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 98. Saudi Arabia somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 99. South Africa somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 100. South Africa somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 101. South Africa somatostatin analogs market, by end use, 2018-2030 (USD Million)
Table 102. UAE somatostatin analogs market, by type, 2018-2030 (USD Million)
Table 103. UAE somatostatin analogs market, by application, 2018-2030 (USD Million)
Table 104. UAE somatostatin analogs market, by end use, 2018-2030 (USD Million)
List of Figures
Figure 1 Somatostatin analogs market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Type outlook (USD Million)
Figure 10 Application outlook (USD Million)
Figure 11 End Use outlook (USD Million)
Figure 12 Competitive landscape
Figure 13 Somatostatin analogs market dynamics
Figure 14 Somatostatin analogs market: Porter’s five forces analysis
Figure 15 Somatostatin analogs market: Pestle analysis
Figure 16 Somatostatin analogs market: Type segment dashboard
Figure 17 Somatostatin analogs market: Type market share analysis, 2024 & 2030
Figure 18 Octreotide market, 2018-2030 (USD Million)
Figure 19 Lanreotide market, 2018-2030 (USD Million)
Figure 20 Pasireotide market, 2018-2030 (USD Million)
Figure 21 Others market, 2018-2030 (USD Million)
Figure 22 Somatostatin analogs market: Application segment dashboard
Figure 23 Somatostatin analogs market: Application market share analysis, 2024 & 2030
Figure 24 Somatostatin analogs market, in Acromegaly, 2018-2030 (USD Million)
Figure 25 Somatostatin analogs market, in NET, 2018-2030 (USD Million)
Figure 26 Somatostatin analogs market, in Others, 2018-2030 (USD Million)
Figure 27 Somatostatin analogs market: End Use segment dashboard
Figure 28 Somatostatin analogs market: End Use market share analysis, 2024 & 2030
Figure 29 Hospitals segment market, 2018-2030 (USD Million)
Figure 30 Clinics segment market, 2018-2030 (USD Million)
Figure 31 Others segment market, 2018-2030 (USD Million)
Figure 32 Somatostatin analogs market revenue, by region
Figure 33 Regional marketplace: Key takeaways
Figure 34 Regional marketplace: Key takeaways
Figure 35 North America somatostatin analogs market, 2018-2030 (USD Million)
Figure 36 U.S. country dynamics
Figure 37 U.S. somatostatin analogs market, 2018-2030 (USD Million)
Figure 38 Canada country dynamics
Figure 39 Canada somatostatin analogs market, 2018-2030 (USD Million)
Figure 40 Mexico country dynamics
Figure 41 Mexico somatostatin analogs market, 2018-2030 (USD Million)
Figure 42 Europe somatostatin analogs market, 2018-2030 (USD Million)
Figure 43 UK country dynamics
Figure 44 UK somatostatin analogs market, 2018-2030 (USD Million)
Figure 45 Germany country dynamics
Figure 46 Germany somatostatin analogs market, 2018-2030 (USD Million)
Figure 47 France country dynamics
Figure 48 France somatostatin analogs market, 2018-2030 (USD Million)
Figure 49 Italy country dynamics
Figure 50 Italy somatostatin analogs market, 2018-2030 (USD Million)
Figure 51 Spain country dynamics
Figure 52 Spain somatostatin analogs market, 2018-2030 (USD Million)
Figure 53 Denmark country dynamics
Figure 54 Denmark somatostatin analogs market, 2018-2030 (USD Million)
Figure 55 Sweden country dynamics
Figure 56 Sweden somatostatin analogs market, 2018-2030 (USD Million)
Figure 57 Norway country dynamics
Figure 58 Norway somatostatin analogs market, 2018-2030 (USD Million)
Figure 59 Russia country dynamics
Figure 60 Russia somatostatin analogs market, 2018-2030 (USD Million)
Figure 61 Asia Pacific somatostatin analogs market, 2018-2030 (USD Million)
Figure 62 India country dynamics
Figure 63 India somatostatin analogs market, 2018-2030 (USD Million)
Figure 64 China country dynamics
Figure 65 China somatostatin analogs market, 2018-2030 (USD Million)
Figure 66 South Korea country dynamics
Figure 67 South Korea somatostatin analogs market, 2018-2030 (USD Million)
Figure 68 Hong Kong country dynamics
Figure 69 Hong Kong somatostatin analogs market, 2018-2030 (USD Million)
Figure 70 Australia country dynamics
Figure 71 Australia somatostatin analogs market, 2018-2030 (USD Million)
Figure 72 Singapore country dynamics
Figure 73 Singapore somatostatin analogs market, 2018-2030 (USD Million)
Figure 74 Japan country dynamics
Figure 75 Japan somatostatin analogs market, 2018-2030 (USD Million)
Figure 76 Thailand country dynamics
Figure 77 Thailand somatostatin analogs market, 2018-2030 (USD Million)
Figure 78 Latin America somatostatin analogs market, 2018-2030 (USD Million)
Figure 79 Brazil country dynamics
Figure 80 Brazil somatostatin analogs market, 2018-2030 (USD Million)
Figure 81 Argentina country dynamics
Figure 82 Argentina somatostatin analogs market, 2018-2030 (USD Million)
Figure 83 Middle East & Africa somatostatin analogs market, 2018-2030 (USD Million)
Figure 84 South Africa country dynamics
Figure 85 South Africa somatostatin analogs market, 2018-2030 (USD Million)
Figure 86 Kuwait country dynamics
Figure 87 Kuwait somatostatin analogs market, 2018-2030 (USD Million)
Figure 88 Saudi Arabia country dynamics
Figure 89 Saudi Arabia somatostatin analogs market, 2018-2030 (USD Million)
Figure 90 South Africa country dynamics
Figure 91 South Africa somatostatin analogs market, 2018-2030 (USD Million)
Figure 92 UAE country dynamics
Figure 93 UAE somatostatin analogs market, 2018-2030 (USD Million)
Figure 94 Company categorization
Figure 95 Company market position analysis
Figure 96 Strategic framework

Companies Mentioned

The major companies featured in this Somatostatin Analogs market report include:
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Eli Lilly and Company
  • Medical Device Business Services, Inc.
  • Johnson & Johnson Services, Inc.
  • Stryker
  • Ultragenyx Pharmaceutical Inc.
  • Alexion Pharmaceuticals, Inc.

Table Information

Report AttributeDetails
No. of Pages90
PublishedMay 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 5.22 Billion
Forecasted Market Value ( USD ) by 2030 $ 11.1 Billion
Compound Annual Growth Rate13.3%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

Somatostatin Analogs Market by Molecule Type, Application, Route Of Administration, End User, Distribution Channel, Dosage Form - Global Forecast to 2030 - Product Image

Somatostatin Analogs Market by Molecule Type, Application, Route Of Administration, End User, Distribution Channel, Dosage Form - Global Forecast to 2030

  • Report
  • 182 Pages
  • Global
From
Acromegaly Treatment Market by Treatment Type, Route of Administration, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Acromegaly Treatment Market by Treatment Type, Route of Administration, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 181 Pages
  • Global
From
Somatostatin Analogs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Somatostatin Analogs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 82 Pages
  • Global
From
Somatostatin Analogs - Global Strategic Business Report - Product Image

Somatostatin Analogs - Global Strategic Business Report

  • Report
  • 94 Pages
  • Global
From
Somatostatin Analog Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Somatostatin Analog Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 77 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.